ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TED TerrAscend Corp

1.32
0.00 (0.00%)
13 Aug 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type
TerrAscend Corp TG:TED Tradegate Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.32 1.38 1.42 0.00 20:59:56

Director Shareholding

27/11/2003 3:35pm

UK Regulatory


RNS Number:5845S
Tepnel Life Sciences PLC
27 November 2003



           Tepnel Life Sciences PLC ('Tepnel' or 'the Company')
                         Directors' Shareholdings


Manchester, UK. 27 November 2003 ...The Company was notified today by Mr Ben
Matzilevich, Chief Executive Officer, that in the recent placing he had
purchased 434,783 ordinary shares of 1p each in the Company ("Ordinary Shares"),
at a price of 11.5p per share. Following this purchase, Mr Matzilevich's total
holding in Tepnel amounts to 934,783 Ordinary Shares, representing 0.71 per
cent. of the issued share capital of the Company.


The Company was notified today by Mr Gron Ffoulkes-Davies, Group Finance
Director, that in the recent placing he had purchased 250,000 ordinary shares of
1p each in the Company ("Ordinary Shares"), at a price of 11.5p per share.
Following this purchase, Mr Ffoulkes-Davies' total holding in Tepnel amounts to
650,000 Ordinary Shares, representing 0.49 per cent. of the issued share capital
of the Company.


For Further Information:



Tepnel Life Sciences plc
Ben Matzilevich, CEO
Gron Ffoulkes-Davies, Finance Director
0161 946 2200



De Facto Communications
Yvonne Alexander
020 7496 3300


Notes to Editors


About Tepnel Life Sciences PLC

Tepnel Life Sciences is a UK-based international life sciences instrumentation
and services company with a 'tri-polar' strategy focused on providing the
biomedical industry with high-throughput automated DNA purification systems,
manual DNA purification kits and reagents, as well as scientific services for
nucleic acid purification, drug analysis, genotyping and genetically modified
foods. Tepnel Life Sciences was founded in 1992 to exploit DNA technology
generated at UMIST (University of Manchester Institute of Science and
Technology) and is quoted on the AIM segment of the London Stock Exchange (AIM:
TED). More information on Tepnel can be found at www.tepnel.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RDSUBVSROKRAUAA

1 Year TerrAscend Chart

1 Year TerrAscend Chart

1 Month TerrAscend Chart

1 Month TerrAscend Chart